[Prognostic factors and better survival rate after the treatment of advanced ovarian cancer with neoadjuvant chemotherapy].
The better survival rate was evaluated as well as the prognostic factors due to the treatment with neoadjuvant chemotherapy for ovarian cancers FIGO Stage III and IV. For the period of 1990 till 2004 - 238 patients with histological diagnosis cystadenocarcinomas were evaluated. 192 patients received conventional chemotherapy after surgical treatment and 46 patients were treated with neoadjuvant chemotherapy after which a secondary cytoreductive surgery was used. The five years survival rate for the neoadjuvant chemotherapy was the same as the five years survival rate from the conventional chemotherapy. The patients with residual tumor < or = 2 cm. had a better prognosis than those with residual tumor more than 2 cm. There was a better prognosis for the patients treated with > or = 18 mg/m2/ week cisplatin from those treated with < 18 mg/m2/week.
Ivanov
S
S
Ivanov
S
S
Khadzhiolov
N
N
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003536:Cystadenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010052:Ovariectomy; D012189:Retrospective Studies
D002945:Cisplatin